Tony Mets
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tony Mets has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Ivan Bautmans
Frailty & Resilience in Ageing (FRIA) Research Unit, Vitality Research Group, Vrije Universiteit Brussel (VUB), Brussels, Belgium;b Gerontology Department, Vrije Universiteit Brussel (VUB), Brussels, Belgium;c Department of Geriatric Physiotherapy, SOMT University of Physiotherapy, The Netherlands;d Geriatrics Department, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium
10 shared publications - Rose Njemini
Vrije Universiteit Brussel
8 shared publications - Lore Decoster
Medical Oncology Department, UZ Brussels, Brussels, Belgium
3 shared publications - Oscar Okwudiri Onyema
Gerontology Department and Frailty in Aging Research (FRIA) Group, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Brussel, Belgium
3 shared publications - Ingo Beyer
Department of Geriatrics, Universitair Ziekenhuis Brussel, Brussels, Belgium
2 shared publications - Louis Nuvagah Forti
Gerontology Department and Frailty in Aging Research (FRIA) Group, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Brussel, Belgium
2 shared publications
Latest Publications
- 1 February 2020
- Published by Elsevier in Experimental Gerontology
- Vol. 130, 110787
Analysis of inflammatory markers and hormones in old cancer patients: A descriptive study
- 1 February 2020
- Published by Elsevier in Experimental Gerontology
- Vol. 130, 110787
Analysis of inflammatory markers and hormones in old cancer patients: A descriptive study
- 1 November 2017
- Published by Elsevier in European Geriatric Medicine
- Vol. 8 (5-6) , 381-382
Proton pump inhibitor-associated acute interstitial nephritis
- 1 November 2017
- Published by Elsevier in European Geriatric Medicine
- Vol. 8 (5-6) , 381-382
Proton pump inhibitor-associated acute interstitial nephritis
- 30 January 2017
- Published by Elsevier in European Geriatric Medicine
- Vol. 8 (2) , 176-177
A twenty-year evolution of a Kaposi's sarcoma
- 30 January 2017
- Published by Elsevier in European Geriatric Medicine
- Vol. 8 (2) , 176-177
A twenty-year evolution of a Kaposi's sarcoma
- Open Access
- 28 December 2015
- Published by Springer Nature in BMC Cancer
- Vol. 15 (1) , 1-11
Shifts in subsets of CD8+ T-cells as evidence of immunosenescence in patients with cancers affecting the lungs: an observational case-control study
Shifts in CD8+ T-cell subsets that are hallmarks of immunosenescence are observed in ageing and in conditions of chronic immune stimulation. Presently, there is limited documentation of such changes in lung cancer and other malignancies affecting the lungs. Changes in CD8+ T-cell subsets, based on the expression of CD28 and CD57, were analysed in patients with various forms of cancer affecting the lungs, undergoing chemotherapy and in a control group over six months, using multi-colour flow cytometry. The differences between patients and controls, and the changes in the frequency of CD8+ T-cell subpopulations among lung cancer patients corresponded to those seen in immunosenescence: lower CD8-/CD8+ ratio, lower proportions of CD28+CD57- cells consisting of naïve and central memory cells, and higher proportions of senescent-enriched CD28-CD57+ cells among the lung cancer patients, with the stage IV lung cancer patients showing the most pronounced changes. Also observed was a tendency of chemotherapy to induce the formation of CD28+CD57+ cells, which, in line with the capacity of chemotherapy to induce the formation of senescent cells, might provide more evidence supporting CD28+CD57+ cells as senescent cells. Immunosenescence was present before the start of the treatment; it appeared to be pronounced in patients with advanced cases of malignancies affecting the lungs, and might not be averted by chemotherapy.
- 28 December 2015
- Published by Springer Nature in BMC Cancer
- Vol. 15 (1) , 1-11
Open AccessShifts in subsets of CD8+ T-cells as evidence of immunosenescence in patients with cancers affecting the lungs: an observational case-control study
Shifts in CD8+ T-cell subsets that are hallmarks of immunosenescence are observed in ageing and in conditions of chronic immune stimulation. Presently, there is limited documentation of such changes in lung cancer and other malignancies affecting the lungs. Changes in CD8+ T-cell subsets, based on the expression of CD28 and CD57, were analysed in patients with various forms of cancer affecting the lungs, undergoing chemotherapy and in a control group over six months, using multi-colour flow cytometry. The differences between patients and controls, and the changes in the frequency of CD8+ T-cell subpopulations among lung cancer patients corresponded to those seen in immunosenescence: lower CD8-/CD8+ ratio, lower proportions of CD28+CD57- cells consisting of naïve and central memory cells, and higher proportions of senescent-enriched CD28-CD57+ cells among the lung cancer patients, with the stage IV lung cancer patients showing the most pronounced changes. Also observed was a tendency of chemotherapy to induce the formation of CD28+CD57+ cells, which, in line with the capacity of chemotherapy to induce the formation of senescent cells, might provide more evidence supporting CD28+CD57+ cells as senescent cells. Immunosenescence was present before the start of the treatment; it appeared to be pronounced in patients with advanced cases of malignancies affecting the lungs, and might not be averted by chemotherapy.
- 1 November 2015
- Published by Elsevier in Archives of Gerontology and Geriatrics
- Vol. 61 (3) , 494-502
Aging-associated subpopulations of human CD8+ T-lymphocytes identified by their CD28 and CD57 phenotypes
- 1 November 2015
- Published by Elsevier in Archives of Gerontology and Geriatrics
- Vol. 61 (3) , 494-502
Aging-associated subpopulations of human CD8+ T-lymphocytes identified by their CD28 and CD57 phenotypes
- 1 September 2015
- Published by Elsevier in Clinical Nutrition
- Vol. 34, S77
SUN-PP146: Validation of Bioelectrical Impedance Analysis (BIA) Equations to Predict Appendicular Skeletal Muscle and Fat Mass in Older Adults with Sarcopenia
- 1 September 2015
- Published by Elsevier in Clinical Nutrition
- Vol. 34, S77
SUN-PP146: Validation of Bioelectrical Impedance Analysis (BIA) Equations to Predict Appendicular Skeletal Muscle and Fat Mass in Older Adults with Sarcopenia
- 1 March 2015
- Vol. 35 (3) , 1481-9
Chemotherapy-induced changes and immunosenescence of CD8+ T-cells in patients with breast cancer.
Changes in sub-populations of cytotoxic (CD8+) T-cells, which are observed in aging and in conditions of chronic immune stimulation, are not well-documented in cancer. Using flow cytometry, CD8+ T-cell subsets were analyzed in patients with breast cancer undergoing DNA-damaging chemotherapy and in an older female control group during a six-month longitudinal study, to explore shifts in CD8+ T-cells and the effect of DNA-damaging chemotherapy on different T-cell sub-populations. As expected, there was a consistent decrease in absolute numbers of leukocytes, lymphocytes, T-cells and CD8+ T-cells during chemotherapy in patients with cancer. Among the T-cells, there was a lower CD8-/CD8+ ratio, persisting over the six months, in patients with cancer compared to controls. The proportion of CD28-CD57+ cells also remained higher among patients with cancer throughout the sampling duration. The number of CD28+CD57- and CD28-CD5- cells decreased faster during DNA-damaging chemotherapy than CD28+CD57+ and CD28-CD57+ cells, while only CD28-CD57- cells showed a significant reconstitutive capacity after six months. Immunosenescence appeared to be pronounced in patients with breast cancer, with senescent CD8+ T-cells playing a role. The normal condition was not restored after six months of chemotherapy.
- 1 March 2015
- Vol. 35 (3) , 1481-9
Chemotherapy-induced changes and immunosenescence of CD8+ T-cells in patients with breast cancer.
Changes in sub-populations of cytotoxic (CD8+) T-cells, which are observed in aging and in conditions of chronic immune stimulation, are not well-documented in cancer. Using flow cytometry, CD8+ T-cell subsets were analyzed in patients with breast cancer undergoing DNA-damaging chemotherapy and in an older female control group during a six-month longitudinal study, to explore shifts in CD8+ T-cells and the effect of DNA-damaging chemotherapy on different T-cell sub-populations. As expected, there was a consistent decrease in absolute numbers of leukocytes, lymphocytes, T-cells and CD8+ T-cells during chemotherapy in patients with cancer. Among the T-cells, there was a lower CD8-/CD8+ ratio, persisting over the six months, in patients with cancer compared to controls. The proportion of CD28-CD57+ cells also remained higher among patients with cancer throughout the sampling duration. The number of CD28+CD57- and CD28-CD5- cells decreased faster during DNA-damaging chemotherapy than CD28+CD57+ and CD28-CD57+ cells, while only CD28-CD57- cells showed a significant reconstitutive capacity after six months. Immunosenescence appeared to be pronounced in patients with breast cancer, with senescent CD8+ T-cells playing a role. The normal condition was not restored after six months of chemotherapy.
- 23 January 2014
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 79 (2) , 75-89
Shortcomings in the Application of Multicolour Flow Cytometry in Lymphocyte Subsets Enumeration
The lymphoid system is composed of numerous phenotypically distinct subsets of cells, each of which has a unique role in the effectiveness of an immune response. To distinguish specifically between these subsets, it is mandatory to detect simultaneously different cell surface antigens. This became feasible by the development of multicolour flow cytometric technologies. With these techniques, researchers now have the opportunity to study individual cells in far greater detail than previously possible. However, proper data analysis, interpretation and presentation of results will require a high level of understanding of the intricacies of the technology and the inherent limitations of the acquired data. The present report is intended to contribute to the better understanding of how the flow cytometer operates. This report may help new and inexperienced users to work appropriately with the flow cytometer.
- 23 January 2014
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 79 (2) , 75-89
Shortcomings in the Application of Multicolour Flow Cytometry in Lymphocyte Subsets Enumeration
The lymphoid system is composed of numerous phenotypically distinct subsets of cells, each of which has a unique role in the effectiveness of an immune response. To distinguish specifically between these subsets, it is mandatory to detect simultaneously different cell surface antigens. This became feasible by the development of multicolour flow cytometric technologies. With these techniques, researchers now have the opportunity to study individual cells in far greater detail than previously possible. However, proper data analysis, interpretation and presentation of results will require a high level of understanding of the intricacies of the technology and the inherent limitations of the acquired data. The present report is intended to contribute to the better understanding of how the flow cytometer operates. This report may help new and inexperienced users to work appropriately with the flow cytometer.
- 1 September 2013
- Published by Elsevier in European Geriatric Medicine
- Vol. 4, S215
Age-related differences in muscle recruitment during a point-to-point reaction-time test
- 1 September 2013
- Published by Elsevier in European Geriatric Medicine
- Vol. 4, S215
Age-related differences in muscle recruitment during a point-to-point reaction-time test
- 1 April 2013
- Published by Wolters Kluwer Health in Alzheimer Disease & Associated Disorders
- Vol. 27 (2) , 123-132
COGNOS
Care plans are intended to improve the independence and functioning of patients with cognitive dysfunction and support the caregivers involved. They are an integral part of the Belgian reimbursement procedure for cholinesterase inhibitors. This nationwide, multicenter, observational study examined the content and implementation of the care plan along with patient satisfaction in community-dwelling patients newly diagnosed with Alzheimer disease in Belgium. The patients' opinion of their quality of life was measured using Anamnestic Comparative Self-Assessment (ACSA) scale. A total of 720 participants (453 female) were enrolled with 86.0% (619/719) living at home alone or with their spouse/partner. Cognitive problems (627/717, 87.4%) were the main reason for initiation of the consultation. Most patients had a caregiver (646/719, 89.8%): generally the spouse/partner (351/646, 54.3%) or a child (232/646, 35.9%). A total of 511 patients (71.0%) were prescribed a cholinesterase inhibitor after the initial consultation. A total of 236 care plans were advised with 169 (71.6%) realized and 157 of these (92.9%) considered adequate. Most patients were satisfied with the help received in the care plan (service satisfaction range, 80.0% to 98.6% of patients). Quality of life as rated by the patient significantly increased between baseline (average ACSA score: 5.2 +/- 2.4) and follow-up (5.8 +/- 2.1). The use of care plans appears to improve management of care for Alzheimer disease patients.
- 1 April 2013
- Published by Wolters Kluwer Health in Alzheimer Disease & Associated Disorders
- Vol. 27 (2) , 123-132
COGNOS
Care plans are intended to improve the independence and functioning of patients with cognitive dysfunction and support the caregivers involved. They are an integral part of the Belgian reimbursement procedure for cholinesterase inhibitors. This nationwide, multicenter, observational study examined the content and implementation of the care plan along with patient satisfaction in community-dwelling patients newly diagnosed with Alzheimer disease in Belgium. The patients' opinion of their quality of life was measured using Anamnestic Comparative Self-Assessment (ACSA) scale. A total of 720 participants (453 female) were enrolled with 86.0% (619/719) living at home alone or with their spouse/partner. Cognitive problems (627/717, 87.4%) were the main reason for initiation of the consultation. Most patients had a caregiver (646/719, 89.8%): generally the spouse/partner (351/646, 54.3%) or a child (232/646, 35.9%). A total of 511 patients (71.0%) were prescribed a cholinesterase inhibitor after the initial consultation. A total of 236 care plans were advised with 169 (71.6%) realized and 157 of these (92.9%) considered adequate. Most patients were satisfied with the help received in the care plan (service satisfaction range, 80.0% to 98.6% of patients). Quality of life as rated by the patient significantly increased between baseline (average ACSA score: 5.2 +/- 2.4) and follow-up (5.8 +/- 2.1). The use of care plans appears to improve management of care for Alzheimer disease patients.